Fusen Pharmaceutical Company Limited provided earnings guidance for the year ended 31 December 2022. For the year, the company expects to record an expected loss attributable to owners of the Company with a range from approximately RMB 30 million to RMB 40 million as compared with the profit attributable to owners of the Company of approximately RMB 16.6 million for the year ended 31 December 2021.